Company intelligence / Profile preview
IntegoGen
Tallahassee, Florida, United Statesintegogen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
IntegoGen has developed placental/amniotic membrane-derived biologic implants for use in surgical and regenerative medicine applications. Their lead program AMP‑001 was evaluated in a Phase 1 clinical trial for hidradenitis suppurativa but the study was withdrawn. Another product, surgiGRAFTnano, is pending further development. The company is AATB-accredited and FDA registered as an HCT/P 361 manufacturer/distributor of birth-tissue derived products[1][2][4].
- Therapeutic areas
- OtherNeurologyDermatologyRheumatology
- Modalities
- BiologicTissue-derived productAllogeneic tissue implantDecellularized tissue matrix (placental/amniotic membrane)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Alliant Biotech LLC (distribution partner for STA Implants)[2]
Beyond the preview
Go deeper on IntegoGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IntegoGen.